Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)
Mirati Will Use FoundationOne® Genomic Profiling Assay to Identify Patients Most Likely to Benefit from Glesatinib
View HTML
Toggle Summary Guardant Health And Mirati Therapeutics Enter Into Collaboration On Glesatinib (MGCD265) In Non Small Cell Lung Cancer (NSCLC) Trial
Mirati to Use Guardant360® Circulating Tumor DNA Diagnostic Test for Glesatinib Patient Selection and Explore the Development of Guardant360® as a Companion Diagnostic Assay
View HTML
Toggle Summary Initial Data from Ongoing Expansion Study of MGCD265 Show Preliminary Evidence of Clinical Efficacy in Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients with MET Gene Alterations
- The First Three Patients Selected for MET Gene Alterations in MGCD265 Dose Expansion Cohort Show Clear Evidence of Tumor Regression<br>- MGCD265 is Well Tolerated in Dose Escalation and Dose Expansion Phases<br>- Data from MGCD265 Phase 1/1b Study Presented at ASCO 2015<br>- Company Also Provided Updates For Ongoing MGCD516 Dose Escalation Study and Mocetinostat Phase 2 Bladder Cancer Study at the Conference
View HTML
Toggle Summary MethylGene Announces Cdn.$26.1 Million Private Placement
NOT FOR DISSEMINATION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
View HTML
Toggle Summary MethylGene Announces Change of President and CEO View HTML
Toggle Summary MethylGene Announces Management Changes View HTML
Toggle Summary MethylGene Announces Plan to Reincorporate in the United States as Mirati Therapeutics, Inc. and List on the NASDAQ View HTML
Toggle Summary MethylGene Announces Presentation of MGCD290 Phase I Clinical Data at Idweek™ 2012 View HTML
Toggle Summary MethylGene Announces the Appointment of Dr. Charles M. Baum as President and CEO and Changes to The Board Of Directors View HTML
Toggle Summary MethylGene Announces the Appointment of Dr. Henry J. Fuchs to its Board of Directors View HTML